Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Sea Limited — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Sea Limited trades at $95.7 (market cap $56.89B). The key difference: Sea Limited is far larger — about 4.5× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Sea Limited for 102 Days on average.
| HALO | SE | |
|---|---|---|
Market Cap | $12.58B | $56.89B |
Volume | 2,179,278 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $188.00 |
52-Week Low | $61.63 | $78.16 |
Typical Hold Time | 1 Days | 102 Days |
Enterprise Value | $14.49B | $51.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sea Limited (SE) trades at $95.25, down 0.62% with a bearish technical signal. The company shows strong fundamental improvement with revenue growing from $12.4B in 2022 to $22.9B in 2025, achieving profitability with net income of $1.58B. Analyst consensus remains strongly bullish with 70% buy ratings and a $153.67 price target, though recent insider selling and technical weakness create near-term headwinds. Operating cash flow has turned positive at $5.02B, supporting the company's growth trajectory.
Sea Limited presents a compelling growth story with improving profitability and strong analyst support, though technical weakness and insider selling warrant caution. The stock trades at a discount to analyst targets with solid fundamentals, but investors should monitor execution risks in competitive e-commerce and digital entertainment markets. The current price level near support at $91-92 offers potential entry for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
